In line with these observations, Rothe et al. identified that several key autophagy genes were differentially expressed in CD34+ hematopoietic stem/progenitor cells, with a prominent role of ATG4B that was differentially expressed in pretreatment CML stem/progenitor cells from subsequent imatinib mesylate (IM) responders vs. IM non-responders (p < 0.05) and was helpful in predicting therapeutic response in CML [94]. This evidence concerns the gene ATG4B and chronic myelogenous leukemia, BCR-ABL1 positive.